Literature DB >> 22824553

Meta-analysis of Prolene Hernia System mesh versus Lichtenstein mesh in open inguinal hernia repair.

Pandanaboyana Sanjay1, David G Watt, Simon A Ogston, Afshin Alijani, John A Windsor.   

Abstract

BACKGROUND: This study was designed to systematically analyse all published randomized clinical trials comparing the Prolene Hernia System (PHS) mesh and Lichtenstein mesh for open inguinal hernia repair.
METHOD: A literature search was performed using the Cochrane Colorectal Cancer Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials in the Cochrane Library, MEDLINE, Embase and Science Citation Index Expanded. Randomized trials comparing the Lichtenstein Mesh repair (LMR) with the Prolene Hernia System were included. Statistical analysis was performed using Review Manager Version 5.1 software. The primary outcome measures were hernia recurrence and chronic pain after operation. Secondary outcome measures included surgical time, peri-operative complications, time to return to work, early and long-term postoperative complications.
RESULTS: Six randomized clinical trials were identified as suitable, containing 1313 patients. There was no statistical difference between the two types of repair in operation time, time to return to work, incidence of chronic groin pain, hernia recurrence or long-term complications. The PHS group had a higher rate of peri-operative complications, compared to Lichtenstein mesh repair (risk ratio (RR) 0.71, 95% confidence interval 0.55-0.93, P=0.01).
CONCLUSION: The use of PHS mesh was associated with an increased risk of peri-operative complications compared to LMR. Both mesh repair techniques have comparable short- and long-term outcomes.
Copyright © 2012 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22824553     DOI: 10.1016/j.surge.2012.06.001

Source DB:  PubMed          Journal:  Surgeon        ISSN: 1479-666X            Impact factor:   2.392


  7 in total

1.  Slow femoral venous flow and venous thromboembolism following inguinal hernioplasty in patients without or with low molecular weight heparin prophylaxis.

Authors:  F S Lozano; J Sánchez-Fernández; J R González-Porras; J García-Alovio; J A Santos; R Mateos; I Alberca
Journal:  Hernia       Date:  2015-02-08       Impact factor: 4.739

2.  Unilateral Lichtenstein tension-free mesh hernia repair and testicular perfusion: a prospective control study.

Authors:  J Aguilar-García; H A Cano-González; M A Martínez-Jiménez; F de la Rosa-Zapata; M Sánchez-Aguilar
Journal:  Hernia       Date:  2018-01-19       Impact factor: 4.739

3.  ULTRAPRO Hernia System versus lichtenstein repair in treatment of primary inguinal hernias: a prospective randomized controlled study.

Authors:  Faruk Karateke; Sefa Ozyazici; Ebru Menekse; Hatice Özdogan; Mevlüt Kunt; Hilmi Bozkurt; İlhan Bali; Mehmet Özdogan
Journal:  Int Surg       Date:  2014 Jul-Aug

4.  International guidelines for groin hernia management.

Authors: 
Journal:  Hernia       Date:  2018-01-12       Impact factor: 4.739

Review 5.  Current treatment concepts for groin hernia.

Authors:  Stavros A Antoniou; Rudolph Pointner; Frank A Granderath
Journal:  Langenbecks Arch Surg       Date:  2014-05-14       Impact factor: 3.445

Review 6.  Update with level 1 studies of the European Hernia Society guidelines on the treatment of inguinal hernia in adult patients.

Authors:  M Miserez; E Peeters; T Aufenacker; J L Bouillot; G Campanelli; J Conze; R Fortelny; T Heikkinen; L N Jorgensen; J Kukleta; S Morales-Conde; P Nordin; V Schumpelick; S Smedberg; M Smietanski; G Weber; M P Simons
Journal:  Hernia       Date:  2014-03-20       Impact factor: 4.739

7.  Rates of and methods used at reoperation for recurrence after primary inguinal hernia repair with Prolene Hernia System and Lichtenstein.

Authors:  J Magnusson; U O Gustafsson; J Nygren; A Thorell
Journal:  Hernia       Date:  2017-12-02       Impact factor: 4.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.